Peter Clark, MD, discusses key updates to NMIBC guidelines, including revisions to risk stratification, the emerging role of biomarkers, and how to navigate treatment options for BCG-unresponsive disease.
|Videos|September 14, 2022
Dr. Kocour and Dr. Murray on embolization of the prostate
Author(s)Urology Times staff
“A majority of the patients who were referred who had a catheter pre embolization are now catheter free,” says Kimberly Kocour, MD.
Advertisement
In this video, Kimberly Kocour, MD, and Katie Murray, DO, MS, discuss the rationale and notable findings from the South Central Section of the AUA Annual Meeting abstract, "Prostatic artery embolization: an option for select male patients with necessary collaboration between urology and interventional radiology." Murray is an assistant professor at the University of Missouri Division of Urology in Columbia. Kocour is a urology resident at the University of Missouri.
Advertisement
Related to this article
The AMA issued separate codes for subfascial and subcutaneous implantation of a tibial neuromodulation device.
Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.
Heather Florio joins to discuss the potential role of supplements in pelvic and sexual health.
John P. Sfakianos, MD, discusses how ctDNA can be optimally integrated into bladder cancer clinical trials.
A recap of the FDA submissions and regulatory decisions in urology from September 2026.
Robert J. Motzer, MD, discusses the significance of the belzutifan plus lenvatinib approval, adverse event management with the combination, and the evolving role of HIF-2α inhibition in ccRCC.
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
Advertisement
Advertisement
Trending on Urology Times
1
AMA issues Category I CPT codes for implantable tibial neuromodulation in UUI
2
Aglatimagene besadenovec shows sustained immune remodeling in localized prostate cancer
3
The UroOnc Minute: Key Updates to the AUA NMIBC Guideline, With Peter E. Clark, MD
4
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
5